SCHEMBL3594397

SCHEMBL3594397

CCN(CC)c1ccc(C=CC(=O)c2cccnc2)c(O)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.69
MAPK1 P28482 1/20 0.69
MAPT P10636 6/20 0.54
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
ALDH1A1 P00352 3/20 0.53
LMNA P02545 3/20 0.53
KDM4E B2RXH2 2/20 0.53
PKM P14618 1/20 0.53
APP P05067 1/20 0.52
GSK3B P49841 1/20 0.52
GFER P55789 2/20 0.51
CYP2C19 P33261 1/20 0.51
CYP1A1 P04798 8/20 0.50
CYP1A2 P05177 8/20 0.50
CYP1B1 Q16678 8/20 0.50
CYP3A4 P08684 5/20 0.50
CYP2D6 P10635 5/20 0.50
HPGD P15428 1/20 0.50
NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594393 1.00 NPSR1 (0.69) NPSR1MAPK1MAPTKMT2AMEN1
SCHEMBL3596019 0.81 ALDH1A1 (0.60) MAPTKMT2AALDH1A1LMNAKDM4E
SCHEMBL3596015 0.81 ALDH1A1 (0.60) MAPTKMT2AALDH1A1LMNAKDM4E
SCHEMBL14195185 0.78 MAPT (0.73) NPSR1MAPK1MAPTKMT2AMEN1
SCHEMBL28520457 0.78 MAPT (0.73) NPSR1MAPK1MAPTKMT2AMEN1
SCHEMBL3597965 0.76 MAPT (0.72) MAPK1MAPTKMT2AMEN1ALDH1A1
SCHEMBL3597959 0.76 MAPT (0.72) MAPK1MAPTKMT2AMEN1ALDH1A1
SCHEMBL3598076 0.74 APP (0.64) MAPTKMT2AALDH1A1LMNAKDM4E
SCHEMBL3598073 0.74 APP (0.64) MAPTKMT2AALDH1A1LMNAKDM4E
SCHEMBL10478008 0.73 MAPT (0.49) NPSR1MAPK1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795249-B2 Certain pyrazoline derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-14 US disclosed
US-20080171754-A1 Certain pyrazoline derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171754-A1 Certain pyrazoline derivatives with kinase inhibitory activity MAP3K5, MAP4K5, MAP3K20 NPSR1 4139/4885MAPK1 201/4885MAPT 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.